{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:43:56Z","timestamp":1789688636764,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970471"],"award-info":[{"award-number":["81970471"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gut microbiota alterations including small intestinal bacterial overgrowth (SIBO) might play a role in pathogenesis of irritable bowel syndrome (IBS). Rifaximin could effectively and safely improve IBS symptoms. The aim of this study was to investigate the effect of rifaximin on Gastrointestinal (GI) symptoms, quality of life (QOL) and SIBO eradication in Chinese IBS-D patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 78 IBS-D patients defined by the Rome IV criteria. Patients received 400\u2009mg rifaximin twice daily for 2\u2009weeks and 10-week follow-up. GI symptoms were assessed at week 0, 2, 4, 8 and 12. QOL and lactulose hydrogen breath test (LHBT) results were estimated at week 0 and 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All participants showed significant improvements in GI symptom subdomains after rifaximin treatment (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), which could maintain at least 10\u2009weeks of follow-up. Additionally, QOL scores were increased with concomitant improvement of clinical symptoms (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). The 45 rifaximin-responsive patients (57.7%) achieved significantly greater GI-symptom improvement than non-responders (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). No GI symptoms were associated with SIBO (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). SIBO normalization after rifaximin treatment measured by LHBT was found in 44.4% (20\/45) of patients with SIBO before treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A short course (2\u2009weeks) of rifaximin improved GI symptoms and QOL in Chinese IBS-D patients whether they had SIBO or not. However, the efficacy of rifaximin could not be explained by the successful eradication of SIBO. Further studies on the therapeutic mechanisms of rifaximin in IBS are urgently needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-020-01336-6","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T03:02:43Z","timestamp":1591930963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome"],"prefix":"10.1186","volume":"20","author":[{"given":"Xiaojun","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishou","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"issue":"6","key":"1336_CR1","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","volume":"150","author":"DA Drossman","year":"2016","unstructured":"Drossman DA, Hasler WL. Rome IV-functional GIdisorders: disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257\u201361.","journal-title":"Gastroenterology."},{"issue":"9","key":"1336_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jama.2015.0954","volume":"313","author":"WD Chey","year":"2015","unstructured":"Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949\u201358.","journal-title":"JAMA."},{"issue":"11","key":"1336_CR3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/j.1365-2036.2004.01939.x","volume":"19","author":"LS Xiong","year":"2004","unstructured":"Xiong LS, Chen MH, Chen HX, Xu AG, Wang WA, Hu PJ, et al. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment Pharmacol Ther. 2004;19(11):1217\u201324.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1336_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12955-017-0611-2","volume":"15","author":"JL Buono","year":"2017","unstructured":"Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1336_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.gtc.2010.12.013","volume":"40","author":"N Agarwal","year":"2011","unstructured":"Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin N Am. 2011;40(1):11\u20139.","journal-title":"Gastroenterol Clin N Am"},{"issue":"1","key":"1336_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/jgh.13987","volume":"33","author":"KA Gwee","year":"2018","unstructured":"Gwee KA, Ghoshal UC, Chen M. Irritable bowel syndrome in Asia: pathogenesis, natural history, epidemiology, and management. J Gastroenterol Hepatol. 2018;33(1):99\u2013110.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"1336_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","volume":"1","author":"GJ Holtmann","year":"2016","unstructured":"Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133\u201346.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"26","key":"1336_CR8","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1056\/NEJMra1607547","volume":"376","author":"AC Ford","year":"2017","unstructured":"Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med. 2017;376(26):2566\u201378.","journal-title":"N Engl J Med"},{"issue":"3\u20134","key":"1336_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10354-017-0592-0","volume":"168","author":"G Moser","year":"2018","unstructured":"Moser G, Fournier C, Peter J. Intestinal microbiome-gut-brain axis and irritable bowel syndrome. Wien Med Wochenschr. 2018;168(3\u20134):62\u20136.","journal-title":"Wien Med Wochenschr"},{"issue":"1","key":"1336_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2019.03.049","volume":"157","author":"R Pittayanon","year":"2019","unstructured":"Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, et al. Gut microbiota in patients with irritable bowel syndrome-a systematic review. Gastroenterology. 2019;157(1):97\u2013108.","journal-title":"Gastroenterology."},{"issue":"5","key":"1336_CR11","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1053\/j.gastro.2016.12.039","volume":"152","author":"F Klem","year":"2017","unstructured":"Klem F, Wadhwa A, Prokop LJ, Sundt WJ, Farrugia G, Camilleri M, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology. 2017;152(5):1042\u201354.","journal-title":"Gastroenterology."},{"key":"1336_CR12","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3389\/fmicb.2018.01600","volume":"9","author":"X Zhuang","year":"2018","unstructured":"Zhuang X, Tian Z, Li L, Zeng Z, Chen M, Xiong L. Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome. Front Microbiol. 2018;9:1600.","journal-title":"Front Microbiol"},{"issue":"12","key":"1336_CR13","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1111\/j.1572-0241.2000.03368.x","volume":"95","author":"M Pimentel","year":"2000","unstructured":"Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"1336_CR14","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.3748\/wjg.v20.i10.2482","volume":"20","author":"UC Ghoshal","year":"2014","unstructured":"Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol. 2014;20(10):2482\u201391.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"1336_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5009\/gnl16126","volume":"11","author":"UC Ghoshal","year":"2017","unstructured":"Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver. 2017;11(2):196\u2013208.","journal-title":"Gut Liver"},{"issue":"7","key":"1336_CR16","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1001\/jama.292.7.852","volume":"292","author":"HC Lin","year":"2004","unstructured":"Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292(7):852\u20138.","journal-title":"JAMA."},{"issue":"9","key":"1336_CR17","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s10620-010-1276-4","volume":"55","author":"ED Shah","year":"2010","unstructured":"Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55(9):2441\u20139.","journal-title":"Dig Dis Sci"},{"issue":"7","key":"1336_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00535-018-1476-9","volume":"53","author":"B Chen","year":"2018","unstructured":"Chen B, Kim JJ, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018;53(7):807\u201318.","journal-title":"J Gastroenterol"},{"issue":"7","key":"1336_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/apt.12456","volume":"38","author":"E Grace","year":"2013","unstructured":"Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowth\u2013prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38(7):674\u201388.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1336_CR20","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/0016-5085(88)90173-4","volume":"95","author":"P Kerlin","year":"1988","unstructured":"Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology. 1988;95(4):982\u20138.","journal-title":"Gastroenterology."},{"issue":"11","key":"1336_CR21","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/j.1365-2036.2005.02493.x","volume":"21","author":"G Nucera","year":"2005","unstructured":"Nucera G, Gabrielli M, Lupascu A, Lauritano EC, Santoliquido A, Cremonini F, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;21(11):1391\u20135.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"1336_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/MEG.0000000000000122","volume":"26","author":"UC Ghoshal","year":"2014","unstructured":"Ghoshal UC, Srivastava D, Ghoshal U, Misra A. Breath tests in thediagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J Gastroenterol Hepatol. 2014;26(7):753\u201360.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"1336_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12325-018-0673-5","volume":"35","author":"BK Rodino-Janeiro","year":"2018","unstructured":"Rodino-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-Garcia R, Santos J. A review of microbiota and irritable bowel syndrome: future in therapies. Adv Ther. 2018;35(3):289\u2013310.","journal-title":"Adv Ther"},{"issue":"Suppl 1","key":"1336_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000081990","volume":"51","author":"C Scarpignato","year":"2005","unstructured":"Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51(Suppl 1):36\u201366.","journal-title":"Chemotherapy."},{"issue":"Suppl 1","key":"1336_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/apt.13437","volume":"43","author":"M Pimentel","year":"2016","unstructured":"Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43(Suppl 1):37\u201349.","journal-title":"Aliment Pharmacol Ther"},{"key":"1336_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2016.32","volume":"7","author":"A Acosta","year":"2016","unstructured":"Acosta A, Camilleri M, Shin A, Linker Nord S, O'Neill J, Gray AV, et al. Effects of Rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. Clin Transl Gastroenterol. 2016;7:e173.","journal-title":"Clin Transl Gastroenterol"},{"issue":"4","key":"1336_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1586\/17474124.2016.1140571","volume":"10","author":"JS Kane","year":"2016","unstructured":"Kane JS, Ford AC. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2016;10(4):431\u201342.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"1336_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1004409","volume":"364","author":"M Pimentel","year":"2011","unstructured":"Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"1336_CR29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","volume":"101","author":"AI Sharara","year":"2006","unstructured":"Sharara AI, Smalley W, Heidelbaugh JJ, Mounzer R, Sidani S, Elhaji I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101(2):326\u201333.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1336_CR30","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","volume":"151","author":"A Lembo","year":"2016","unstructured":"Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat treatment with Rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113\u201321.","journal-title":"Gastroenterology."},{"issue":"1","key":"1336_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/ajg.2011.355","volume":"107","author":"SB Menees","year":"2012","unstructured":"Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107(1):28\u201335.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1336_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.13928","volume":"45","author":"L Gatta","year":"2017","unstructured":"Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604\u201316.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"1336_CR33","first-page":"1","volume":"29","author":"A Gasbarrini","year":"2009","unstructured":"Gasbarrini A, Corazza GR, Gasbarrini G, Montalto M, Di Stefano M, Basilisco G, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome consensus conference. Aliment Pharmacol Ther. 2009;29(Suppl 1):1\u201349.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1336_CR34","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/ajg.2017.46","volume":"112","author":"A Rezaie","year":"2017","unstructured":"Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the north American consensus. Am J Gastroenterol. 2017;112(5):775\u201384.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"1336_CR35","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.cgh.2009.06.031","volume":"7","author":"AC Ford","year":"2009","unstructured":"Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279\u201386.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1336_CR36","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3346\/jkms.2015.30.6.757","volume":"30","author":"S Bae","year":"2015","unstructured":"Bae S, Lee KJ, Kim YS, Kim KN. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects. J Korean Med Sci. 2015;30(6):757\u201362.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"1336_CR37","first-page":"412","volume":"98","author":"M Pimentel","year":"2003","unstructured":"Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"1336_CR38","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/apt.12479","volume":"38","author":"SC Shah","year":"2013","unstructured":"Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38(8):925\u201334.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1336_CR39","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","volume":"101","author":"AI Sharara","year":"2006","unstructured":"Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101(2):326\u201333.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1336_CR40","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1053\/j.gastro.2014.09.001","volume":"147","author":"DS Weinberg","year":"2014","unstructured":"Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S. American Gastroenterological Association Institute guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147(5):1146\u20138.","journal-title":"Gastroenterology."},{"key":"1336_CR41","doi-asserted-by":"crossref","unstructured":"Sherwin LB, Deroche CB, Krisanabud P, Matteson-Kome M, Bechtold M, Ruppar T. Adherence to short-course pharmacotherapy in adults with irritable bowel syndrome. West J Nurs Res. 2019;1918313053.","DOI":"10.1177\/0193945919872419"},{"issue":"9","key":"1336_CR42","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1177\/1756283X17726087","volume":"10","author":"BD Cash","year":"2017","unstructured":"Cash BD, Pimentel M, Rao S, Weinstock L, Chang L, Heimanson Z, et al. Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Ther Adv Gastroenterol. 2017;10(9):689\u201399.","journal-title":"Ther Adv Gastroenterol"},{"issue":"3","key":"1336_CR43","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s10620-018-5344-5","volume":"64","author":"AK Tuteja","year":"2019","unstructured":"Tuteja AK, Talley NJ, Stoddard GJ, Verne GN. Double-blind placebo-controlled study of Rifaximin and lactulose hydrogen breath test in gulf war veterans with irritable bowel syndrome. Dig Dis Sci. 2019;64(3):838\u201345.","journal-title":"Dig Dis Sci"},{"key":"1336_CR44","unstructured":"Xifaxan (rifaximin) tablets, for oral use (package insert). Salix Pharmaceuticals: Bridgewater, NJ 2015."},{"key":"1336_CR45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/CEG.S89999","volume":"8","author":"S Soldi","year":"2015","unstructured":"Soldi S, Vasileiadis S, Uggeri F, Campanale M, Morelli L, Fogli MV, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015;8:309\u201325.","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"1336_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/19490976.2018.1460013","volume":"10","author":"AA Fodor","year":"2019","unstructured":"Fodor AA, Pimentel M, Chey WD, Lembo A, Golden PL, Israel RJ, et al. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes. 2019;10(1):22\u201333.","journal-title":"Gut Microbes"},{"key":"1336_CR47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2147\/CEG.S167031","volume":"11","author":"C Chang","year":"2018","unstructured":"Chang C. Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin. Clin Exp Gastroenterol. 2018;11:335\u201345.","journal-title":"Clin Exp Gastroenterol"},{"issue":"8","key":"1336_CR48","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","volume":"44","author":"ZD Jiang","year":"2000","unstructured":"Jiang ZD, Ke S, Palazzini E, Riopel L, DuPont HL. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44(8):2205\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1336_CR49","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ijantimicag.2013.12.008","volume":"43","author":"A Pistiki","year":"2014","unstructured":"Pistiki A, Galani I, Pyleris E, Barbatzas C, Pimentel M, Giamarellos-Bourboulis EJ. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents. 2014;43(3):236\u201341.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"1336_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060042","volume":"8","author":"JS Bajaj","year":"2013","unstructured":"Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8(4):e60042.","journal-title":"PLoS One"},{"issue":"48","key":"1336_CR51","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.3748\/wjg.15.6068","volume":"15","author":"K Kajander","year":"2009","unstructured":"Kajander K, Myllyluoma E, Kyronpalo S, Rasmussen M, Sipponen P, Mattila I, et al. Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome. World J Gastroenterol. 2009;15(48):6068\u201374.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1336_CR52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijantimicag.2009.11.013","volume":"35","author":"ZD Jiang","year":"2010","unstructured":"Jiang ZD, Ke S, DuPont HL. Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents. 2010;35(3):278\u201381.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"1336_CR53","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.gastro.2013.10.026","volume":"146","author":"D Xu","year":"2014","unstructured":"Xu D, Gao J, Gillilland M, Wu X, Song I, Kao JY, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014;146(2):484\u201396.","journal-title":"Gastroenterology."},{"issue":"25","key":"1336_CR54","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.3748\/wjg.v23.i25.4491","volume":"23","author":"FR Ponziani","year":"2017","unstructured":"Ponziani FR, Zocco MA, D'Aversa F, Pompili M, Gasbarrini A. Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol. 2017;23(25):4491\u20139.","journal-title":"World J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01336-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-020-01336-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01336-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T19:19:25Z","timestamp":1623439165000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-01336-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-01336-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-17901\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"13 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Medical Ethical Committee of the First Affiliated Hospital of Sun Yat-sen University. All patients had signed informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}